Clinical Trial Update: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating iodine-131 labeled anti-B1 antibody with CHOP for untreated mantle cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Iodine-131 anti-B1 antibody + CHOP (iodine-131 labeled anti-B1 antibody with CHOP)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: COMPLETED | Results posted: 2014-04-08